Pyrethroids and the striatal dopaminergic system in vivo.
1. Type I (permethrin and allethrin) or type II (cypermethrin and fenvalerate) pyrethroids caused 23-37% increases in the striatal content of the dopamine metabolite 3,4-dihydroxyphenylacetic acid (DOPAC). 2. Toxicity symptoms and increases in DOPAC were associated with higher brain concentrations for type I (2.6-5.8 micrograms/gm) than type II pyrethroids (0.4-0.6 micrograms/gm). 3. No specific difference in the interaction between type I and II pyrethroids and the striatal dopaminergic system were recognized.
Doherty
J D
JD
Radioisotope Research Center, Kyoto University, Japan.
Morii
N
N
Hiromori
T
T
Ohnishi
J
J
D015102:3,4-Dihydroxyphenylacetic Acid / Q000494:pharmacology; D000487:Allethrins / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001923:Brain Chemistry / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects; D008297:Male; D009570:Nitriles; D026023:Permethrin; D011722:Pyrethrins / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D011954:Receptors, Dopamine / Q000187:drug effects*
D000487:Allethrins; D009570:Nitriles; D011722:Pyrethrins; D011954:Receptors, Dopamine; D015102:3,4-Dihydroxyphenylacetic Acid; C017160:cypermethrin; D026023:Permethrin; C017690:fenvalerate